AVITA Medical Reports 4% Revenue Growth and $10.6M Net Loss in Q1 2026

BARDA Agreement Provides Steady Revenue Stream and Strategic Validation

AVITA Medical (ASX:AVH) has locked in a significant 10-year contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA), valued at up to $25.5 million. This deal, announced in early April, secures recurring readiness revenue through maintaining an inventory of RECELL products for emergency burn response and supporting surge procurement capabilities. The agreement underscores AVITA’s role in U.S. burn emergency preparedness and adds a stable revenue component to its commercial portfolio.

Clinical Data on Cohealyx Signals Potential Shift in Wound Care Practices

Interim results from the Cohealyx I post-market clinical study revealed a striking reduction in mean time to skin grafting readiness; 13.6 days compared to a 33.2-day literature benchmark (p<0.001). This approximately 20-day acceleration in grafting readiness, supported by 90% investigator satisfaction, suggests Cohealyx could meaningfully improve patient outcomes and hospital efficiencies. The data, showcased at the American Burn Association meeting, may catalyse broader adoption of Cohealyx alongside RECELL in staged wound management approaches. This clinical momentum complements AVITA’s expanding product mix, which now includes PermeaDerm and RECELL GO mini, targeting smaller wounds and trauma cases.

Financial Performance Reflects Early Signs of Operational Stability

For the quarter ended March 31, 2026, AVITA reported total revenue of approximately US$19.3 million, a 4% increase year-over-year and a 10% sequential rise, driven by Cohealyx contributions and normalising RECELL utilisation following previous reimbursement challenges. The gross profit margin softened slightly to 81.7%, influenced by product mix shifts and inventory adjustments, with RECELL-only margins remaining robust at 85%. Operating expenses declined 11% to $24.5 million, reflecting disciplined cost management and a leaner sales force.

Despite a net loss of $10.6 million, this represents a 23% improvement from the prior year’s $13.9 million loss. The company’s CFO highlighted that cash use of $9.9 million in Q1 was elevated due to seasonal compensation and timing of collections but expects a significant reduction in Q2 as these factors normalise. AVITA ended the quarter with $14.3 million in cash and marketable securities, supported by a recently refinanced $60 million credit facility that provides operational flexibility aligned with its revenue trajectory.

Leadership Changes and Regulatory Clearances Signal Strategic Focus

AVITA appointed Cary Vance as President and CEO following a comprehensive search, signalling confidence in the company’s strategic direction and operational progress. Jan Stern Reed was named independent Chair of the Board, replacing her prior role as Lead Independent Director. These leadership moves coincide with the company receiving regulatory clearance for RECELL GO in Australia and New Zealand, opening new international commercial markets and supporting global expansion plans.

Outlook and Market Positioning Amidst Ongoing Challenges

AVITA reaffirmed its full-year 2026 revenue guidance of US$80 to $85 million, targeting 12% to 19% growth over 2025. The company’s commercial strategy remains focused on approximately 200 U.S. burn and trauma centers, aiming to establish RECELL as the standard of care while expanding Cohealyx and PermeaDerm adoption. However, the company continues to face challenges including reimbursement dynamics, macroeconomic pressures, and the need for additional liquidity, as highlighted by its going concern disclosure and debt obligations.

Investors may find interest in how AVITA balances its expanding product portfolio and clinical validation against cost discipline and capital management. The ongoing Cohealyx trial and BARDA partnership represent tangible catalysts, while the company’s ability to execute on its commercial strategy and manage cash flow will be critical in the coming quarters. The company’s recent $60M credit facility refinancing provides a financial buffer, yet the path to sustained profitability remains to be proven.

Meanwhile, the interim Cohealyx data, which shows a substantial reduction in grafting time, echoes findings from the recent Cohealyx study reducing grafting time, underscoring potential clinical and economic benefits that could reshape acute wound care protocols.